How should vaginal/genital herpes be treated, including dosing for initial outbreak, recurrent episodes, suppressive therapy, and special considerations for pregnancy and immunocompromised patients?

Treatment of Vaginal/Genital Herpes

For first-episode genital herpes, start valacyclovir 1 g orally twice daily for 7–10 days, which offers superior convenience and comparable efficacy to acyclovir. 1

First Clinical Episode

Recommended oral antiviral regimens (all equally effective):

• Valacyclovir 1 g orally twice daily for 7–10 days (preferred for convenience) 1
• Acyclovir 400 mg orally three times daily for 7–10 days 1
• Acyclovir 200 mg orally five times daily for 7–10 days 1
• Famciclovir 250 mg orally three times daily for 7–10 days 1

Extend treatment beyond 10 days if healing is incomplete. 1 For large ulcerative lesions, continue therapy for at least 2 weeks to achieve complete clinical resolution. 1

Critical pitfall: Topical acyclovir is substantially less effective than oral therapy and does not improve systemic symptoms, viremia, or viral shedding from the cervix, urethra, or pharynx—never use it as monotherapy. 1

Recurrent Episodes (Episodic Therapy)

Initiate treatment during prodrome or within 24 hours of lesion onset when viral replication peaks—this timing is critical for maximal benefit. 1

Recommended 5-day regimens:

• Valacyclovir 500 mg orally twice daily 1
• Acyclovir 800 mg orally twice daily 1
• Acyclovir 400 mg orally three times daily 1
• Famciclovir 125 mg orally twice daily 1

Provide patients with a prescription to self-initiate at the first sign of recurrence—delaying treatment beyond 24 hours significantly reduces efficacy. 1

Suppressive Therapy

Offer daily suppressive therapy to patients with ≥6 recurrences per year—this reduces recurrence frequency by ≥75% and decreases asymptomatic viral shedding. 1

Dosing based on recurrence frequency:

For patients with <10 recurrences per year:

• Valacyclovir 500 mg orally once daily 1, 2
• Acyclovir 400 mg orally twice daily 1

For patients with ≥10 recurrences per year:

• Valacyclovir 1 g orally once daily 1, 2
• Famciclovir 250 mg orally twice daily 1

Important: Valacyclovir 500 mg once daily is less effective in patients with ≥10 recurrences per year—use the higher 1 g daily dose or twice-daily regimens instead. 1

After 1 year of continuous suppressive therapy, discontinue temporarily to reassess recurrence frequency, as natural decline often occurs over time. 1

Safety data: Acyclovir has documented safety for up to 6 years of continuous use; valacyclovir and famciclovir for 1 year. 1

Severe Disease Requiring Hospitalization

For disseminated infection, encephalitis, pneumonitis, hepatitis, meningitis, or inability to tolerate oral medication:

• Acyclovir 5–10 mg/kg IV every 8 hours for 5–7 days or until clinical resolution 1

For first-episode HSV-2 meningitis: Start IV acyclovir 10 mg/kg every 8 hours until fever and headache resolve, then transition to oral valacyclovir 1 g three times daily to complete a 14-day course. 1

Special Populations

Pregnancy

Antiviral prophylaxis from 36 weeks gestation until delivery is recommended for women with either first or recurrent episodes to reduce term-time recurrences and cesarean delivery rates. 1

Perform cesarean delivery when any of the following are present at labor onset:

• Suspected or confirmed first-episode genital herpes 1
• First episode occurring <6 weeks before delivery 1
• Prodrome or visible lesions at labor onset 1

Neonatal transmission risk: 25–44% with primary episode at delivery versus ≈1% with recurrent infection. 1

Women receiving acyclovir or valacyclovir during pregnancy should be reported to the manufacturer's pregnancy registry. 3

HIV-Infected/Immunocompromised Patients

Higher dosing is required: Acyclovir 400 mg orally three to five times daily until clinical resolution. 3, 1

For suppressive therapy in HIV-infected patients: Valacyclovir 500 mg orally twice daily (not once daily) is required for adequate viral control. 1

Critical warning: Valacyclovir doses of 8 g per day have been associated with hemolytic uremic syndrome/thrombotic thrombocytopenic purpura in immunocompromised patients—never exceed recommended doses. 3

Daily suppressive therapy reduces HIV RNA concentrations in plasma and genital secretions, though its impact on HIV transmission remains uncertain. 1

Antiviral Resistance

Suspect acyclovir resistance if lesions fail to improve within 7–10 days of appropriate therapy. 1

Confirm with viral culture and susceptibility testing. 1 Resistance is uncommon in immunocompetent patients (<0.5%) but more frequent in immunocompromised individuals, especially those with HIV on long-term suppressive therapy. 1

For confirmed acyclovir-resistant HSV:

• IV foscarnet 40 mg/kg every 8 hours until clinical resolution (first-line for resistant cases) 1
• Topical cidofovir, trifluridine, or imiquimod for external lesions (requires prolonged application ≈21–28 days) 1

All acyclovir-resistant strains are resistant to valacyclovir, and most are resistant to famciclovir. 3

Renal Impairment

Assess renal function before starting and during antiviral therapy—adjust dosing frequency or total daily dose according to creatinine clearance to avoid toxicity. 1

Essential Patient Counseling

Transmission risk:

• Abstain from all sexual activity when lesions or prodromal symptoms are present 1
• Asymptomatic viral shedding can occur even on suppressive therapy, posing ongoing transmission risk 1
• HSV-2 causes more frequent asymptomatic shedding than HSV-1, particularly during the first 12 months after infection 1
• Use condoms during all sexual encounters with new or uninfected partners, though condoms do not completely eliminate transmission risk 1
• Inform all sexual partners about the genital herpes diagnosis 1

Disease course:

• Genital herpes is a chronic, incurable infection with potential for lifelong recurrences 1
• Antiviral medications control symptoms but do not eradicate the virus or prevent all recurrences 1
• HSV-1 causes 5–30% of first-episode genital herpes cases, with much less frequent clinical recurrences than HSV-2 1